Use of Proton pump inhibitors is associated with Lower Hemog
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
People with cystic fibrosis (PwCF) are often administered proton pump inhibitors (PPIs) and histamine H2receptor antagonists (H2RAs) to treat GERD and/or protect pancreatic enzymes from degradation in the stomach. By limiting enteral iron absorption, acid suppressive medications (ASMs) could potentially lower hemoglobin (Hgb) levels.

Researchers used unadjusted and covariate-adjusted generalized linear mixed models (GLMMs) to estimate the fixed effects of using versus never using ASMs on annual Hgb levels of PwCF in the U.S. Cystic Fibrosis Foundation Patient Registry (CFFPR).

Results:
--There were 9850 users and 9007 never-users of ASMs who met inclusion criteria.

--Not adjusting for covariates, Hgb estimates were lower for male and female H2RA and/or PPI users versus never-users.

--Adjusting for covariates, mean Hgb was 0.1 g/dl lower for males that exclusively used PPIs than it was for male never-users of ASMs.

--Adjusting for covariates, mean Hgb levels were 0.11 g/dl lower for females that exclusively used PPIs and 0.16 g/dl lower for females that used PPIs and H2RAs concurrently than it was for female never-users of ASMs.

Conclusively, Males and females with cystic fibrosis (CF) who used PPIs and females with CF who concurrently used PPIs and H2RAs had lower Hgb levels than never-users of ASMs of the same sex in the CFFPR.

Source: https://onlinelibrary.wiley.com/doi/10.1002/ppul.25431?af=R
Like
Comment
Share